EGFR and cancer: EGFR, an early oncogene, is a key target in clinical oncology, frequently activated by mutations or overexpression across human cancers, notably in pancreatic adenocarcinoma with poor prognosis, and lung and colon cancers with detected mutations.80–85 Table 2 summarizes the information regarding mutations and their role in different diseases.